非瓣膜性房颤患者使用直接口服抗凝药与华法林的真实世界结局比较
该回顾性观察研究利用Humana研究数据库2012至2015年医保索赔数据,倾向评分匹配后比较房颤患者启动DOAC或华法林的临床结局。DOAC组缺血性卒中、出血性卒中、系统性栓塞及复合终点风险显著低于华法林组,出血风险无统计学差异,总医疗费用更低。
要点
- DOAC组缺血性卒中风险显著低于华法林组(HR 0.88,95%CI 0.79-0.98)。
- DOAC组出血性卒中和系统性栓塞风险显著低于华法林组。
- 两组出血风险无统计学差异,DOAC组年化总医疗费用更低。
核心结论
- 房颤患者使用DOAC相比华法林缺血性卒中、出血性卒中、系统性栓塞及卒中或栓塞复合终点发生率更低。
- 两组出血率无显著差异,DOAC组总医疗费用更低。
研究设计与样本
- 回顾性观察性研究,使用Humana研究数据库的Medicare Advantage处方药和完全投保商业索赔数据。
- 纳入2012年1月1日至2015年9月30日启动DOAC或华法林的房颤患者,以首次处方日期为索引日期。
- DOAC组与华法林组按倾向评分匹配,采用Cox比例风险模型比较临床结局。
主要发现
- DOAC组缺血性卒中风险显著低于华法林组(HR 0.88;95%CI 0.79-0.98)。
- DOAC组出血性卒中风险显著低于华法林组(HR 0.65;95%CI 0.46-0.92)。
- DOAC组系统性栓塞风险显著低于华法林组(HR 0.53;95%CI 0.43-0.65)。
- DOAC组卒中或系统性栓塞复合终点风险显著低于华法林组(HR 0.78;95%CI 0.71-0.86)。
- 出血风险无统计学差异(HR 0.85;95%CI 0.71-1.01),DOAC组年化药费更高但年化医疗费用和总费用更低。
临床怎么用
- 在非瓣膜性房颤患者抗凝选择中,DOAC可考虑作为优先于华法林的方案以降低卒中和栓塞风险。
- 临床决策需结合患者出血风险、费用及个体情况综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare patients with atrial fibrillation (AF) initiating direct oral anticoagulants (DOACs) versus warfarin on clinical outcomes including stroke, systemic embolism (SE), bleeding events, and cost of care. METHODS: This retrospective observational study used Medicare Advantage Prescription Drug and fully insured commercial claims from the Humana Research Database. Patients with AF who initiated a DOAC or warfarin from January 1, 2012, through September 30, 2015, were included. Date of the first prescription of DOAC or warfarin was the index date. Patients in the DOAC and warfarin groups were matched on propensity scores. Patients were censored at end of enrollment or study period, discontinuation, or switch of index medication. Clinical outcomes were compared in the matched groups using Cox proportional hazards models. Annualized costs and costs adjusted for censoring using Lin's interval method were also compared between the two cohorts. RESULTS: Patients on DOACs had a significantly lower risk of ischemic stroke (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.79-0.98), hemorrhagic stroke (HR, 0.65; CI, 0.46-0.92), SE (HR, 0.53; 95% CI, 0.43-0.65), and composite outcome of stroke or SE (HR, 0.78; 95% CI, 0.71-0.86) compared with patients on warfarin. Bleeding risk was not statistically significant (HR, 0.85; 95% CI, 0.71-1.01). While annualized pharmacy costs were higher, annualized medical and total costs were lower in the DOAC group compared with the warfarin group. CONCLUSION: The results of the study indicated that patients on DOACs had lower rates of ischemic stroke, hemorrhagic stroke, SE, and composite outcome of stroke or SE compared with patients on warfarin. No significant differences in bleeding rates between the DOAC and warfarin groups were observed, while total cost of care was lower in the DOAC group.
引用
- Datar M, Crivera C, Rozjabek H, et al. Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin. Am J Health Syst Pharm. 2019. PMID: 30698654. doi:10.1093/ajhp/zxy032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。